SURGERY FOLLOWED BY CHEMORADIOTHERAPY + C225 FOR HEAD AND NECK CARCINOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 (摘自ClinicalTrials.gov) 这项研究不再招募病人。 原理：诸如西妥昔单抗这样的单抗可以定位肿瘤细胞，并在不损害正常细胞的情况下杀死它们或向它们输送肿瘤杀伤物质。化疗中使用的药物，如顺铂和多西紫杉醇，以不同的方式阻止肿瘤细胞分裂，从而停止生长或死亡。放射疗法使用高能X射线来破坏肿瘤细胞。顺铂和多西紫杉醇可能会使肿瘤细胞对放射治疗更加敏感。将单抗与放化疗相结合，并在手术后给予，可能会杀死所有剩余的肿瘤细胞。 目的：这项随机的II期试验正在研究辅助剂西妥昔单抗联合使用顺铂的放化疗，以了解在接受切除的III期或IV期鳞状细胞癌(癌症)或头颈部淋巴上皮瘤的患者中，它与辅助剂西妥昔单抗联合使用多西紫杉醇的疗效如何。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov) This study is no longer recruiting patients. RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells more sensitive to radiation therapy. Combining a monoclonal antibody with chemoradiotherapy and giving them after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying adjuvant cetuximab given together with chemoradiotherapy using cisplatin to see how well it works compared to adjuvant cetuximab given together with chemoradiotherapy using docetaxel in treating patients with resected stage III or stage IV squamous cell carcinoma (cancer) or lymphoepithelioma of the head and neck.